STOCKS TELEGRAPH

Tag: GH Research

  • 3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

    3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

    Across biotechnology and healthcare markets, investor sentiment is closely influenced by the pace and significance of clinical milestones achieved by emerging therapies. While short-term volatility is not uncommon, sustained market interest is often centered on solutions that address critical gaps in current standards of care.

    GH Research PLC (GHRS)

    GH Research PLC (NASDAQ: GHRS) opened trading on May 12, 2026, with great promise as it jumped 1.32% to $21.54. During the day, the stock rose to $21.75 and sank to $20.89. Taking a long-term approach, GHRS posted a 52-week range of $9.46-$24.66.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 162.03%. Meanwhile, its Annual Earnings per share during the time were -162.03%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -84.53%. This publicly-traded company’s shares outstanding now amount to $62.03 million, simultaneously with a float of $49.37 million. The organization now has a market capitalization of $1.48 billion.

    Nutex Health Inc (NUTX)

    Nutex Health Inc (NASDAQ: NUTX) started the day on May 12, 2026, with a price increase of 1.96% at $135.48. During the day, the stock rose to $135.53 and sank to $128.01. Taking a long-term approach, NUTX posted a 52-week range of $77.21-$193.07.

    Nevertheless, the stock’s Earnings Per Share (EPS) this year is 100.57%. This publicly-traded company’s shares outstanding now amount to $6.95 million, simultaneously with a float of $4.74 million. The organization now has a market capitalization of $932.28 million. Its Quick Ratio in the last reported quarter now stands at 3.12.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved markets. By expanding beyond recurrent pericarditis, the company is positioning itself to participate in areas where inflammation and fibrosis remain important drivers of disease progression.

    Market Momentum

    As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares compared to an average volume of 689,450 shares. The company currently maintains a market capitalization of $150.768M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 suggests substantial upside potential tied to pipeline advancement and future clinical milestones.

    Pipeline Development: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, two biological mechanisms strongly associated with declining cardiac function and progressive heart disease.

    Market Opportunity

    Heart failure represents one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite multiple treatment options already available, unmet need remains for therapies capable of directly addressing inflammatory and fibrotic pathways that contribute to disease progression.

    Outlook

    As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the company’s pipeline may strengthen its long-term positioning within the cardiovascular biotechnology sector.

  • Pre-Market Boost For GH Research (GHRS) As Investors React To Trial Success

    Pre-Market Boost For GH Research (GHRS) As Investors React To Trial Success

    GH Research PLC (NASDAQ: GHRS) witnessed a substantial surge in its stock value today after announcing highly favorable results from a pivotal clinical trial. As of the latest pre-market update, GHRS shares had climbed by an impressive 88.40%, reaching $19.97.

    Stock Performance and Investment Insights

    The remarkable upswing follows the company’s disclosure that its primary endpoint was successfully met in a randomized, double-blind, placebo-controlled Phase 2b trial evaluating GH001, an inhalable mebufotenin therapy, for treatment-resistant depression (TRD). To further discuss these findings, GH Research is scheduled to hold a conference call and live webcast later today.

    The stock has an impressive ST score of 51 on our screener. Investors seeking comparable Biotechnology stocks with higher scores of 60 and above can explore options via our ST screener link.

    Promising Results

    81 individuals with a diagnosis of TRD were included in the Phase 2b study (GH001-TRD-201). Of them, GH001 was given to 40 patients and a placebo to 41. Crucially, the research design did not include psychotherapy therapies. The main outcome of the experiment showed a significant decline in Montgomery-Åsberg Depression Rating Scale (MADRS) scores. In sharp contrast to the 0.3-point gain seen in the placebo group, GH001 users showed an average drop of 15.2 points from baseline on Day 8.

    Secondary endpoints also verified GH001’s effectiveness. GH001’s therapeutic promise in treating TRD was confirmed by statistically and clinically significant improvements on the Clinical Global Impression-Severity scale, the Hamilton Anxiety Rating Scale, and the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form.

    Ongoing Observations and Future Prospects

    As of January 22, 2025, nine patients remain in the open-label extension (OLE) phase, while 54 have completed the study and 18 have exited prematurely. Among OLE completers, 77.8% achieved remission by the six-month mark, with 63% requiring only one to four GH001 treatments within this period. While the OLE safety analysis is still underway, no serious adverse events have been reported thus far.

    These groundbreaking Phase 2b findings underscore GH Research’s pivotal role in advancing interventional psychiatry. With GH001’s potential to redefine TRD treatment through rapid and sustained symptom relief, the company is poised for significant commercial success and broader clinical adoption.